US Bancorp
XENE icon

US Bancorp’s Xenon Pharmaceuticals XENE Stock Holding History

US Bancorp’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.6K Sell
258
-14
-5% -$777 ﹤0.01% 3299
2026
Q1 		$15.8K Buy
272
+97
+55% +$4.47K ﹤0.01% 3200
2025
Q4 		$7.84K Hold
175
– – ﹤0.01% 3403
2025
Q3 		$7.03K Sell
175
-6
-3% -$211 ﹤0.01% 3430
2025
Q2 		$5.67K Sell
181
-94
-34% -$3.07K ﹤0.01% 3603
2025
Q1 		$9.23K Sell
275
-311
-53% -$11.8K ﹤0.01% 3463
2024
Q4 		$23K Sell
586
-20
-3% -$827 ﹤0.01% 3097
2024
Q3 		$23.9K Sell
606
-45
-7% -$1.81K ﹤0.01% 3060
2024
Q2 		$25.4K Sell
651
-913
-58% -$36.5K ﹤0.01% 2965
2024
Q1 		$67.3K Buy
1,564
+631
+68% +$29K ﹤0.01% 2545
2023
Q4 		$43K Buy
933
+674
+260% +$23.8K ﹤0.01% 2750
2023
Q3 		$8.85K Hold
259
– – ﹤0.01% 3220
2023
Q2 		$9.97K Buy
+259
New +$10.3K ﹤0.01% 3263

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

US Bancorp's XENE Position: Q2 2026 in Review

US Bancorp reduced its Xenon Pharmaceuticals (XENE) stake by 5.1% in Q2 2026, selling an estimated $777 and leaving 258 shares worth $15.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3299.

US Bancorp first reported a position in XENE in Q2 2023 and has held it in 13 quarters since. The position peaked at $67.3K in Q1 2024. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • US Bancorp held 258 shares of Xenon Pharmaceuticals worth $15.6K as of Q2 2026.
  • US Bancorp sold 14 Xenon Pharmaceuticals shares in Q2 2026, an estimated $777.
  • Xenon Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3299 holding.
  • US Bancorp first reported a position in Xenon Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • US Bancorp's Xenon Pharmaceuticals position peaked at $67.3K in Q1 2024.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.